Drugs / E6 TCR
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02280811 | Oct 2014 → Jun 2016 | anus cancer, cervical cancer, oropharynx cancer, penile cancer +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E6 TCR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02280811 ↗ |
| Modality | Cell therapy | “autologous T cells transduced with an anti-HPV-16 E6 TCR” NCT02280811 ↗ |
| Route | Intravenous | “cells will be infused intravenously (IV)” NCT02280811 ↗ |